Search Results for "Immunizations"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Immunizations. Results 51 to 60 of 180 total matches.
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old ...
On May 10, 2021, the FDA expanded its Emergency
Use Authorization (EUA) for the Pfizer/BioNTech
mRNA-based COVID-19 vaccine to include adolescents
12-15 years old.1The vaccine has been
authorized for use in persons ≥16 years old since
December 2020.
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Children 5-11 Years Old
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021 (Issue 1638)
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Children 5-11 Years Old ...
The FDA has issued an Emergency Use Authorization
(EUA) for a lower-strength (10 mcg/0.2 mL) formulation
of the mRNA-based COVID-19 vaccine
manufactured by Pfizer/BioNTech (Comirnaty) for use
in children 5-11 years old. The original formulation
of (Comirnaty) (30 mcg/0.3 mL) is FDA-licensed for
use in persons ≥16 years old and available under an
EUA for use in adolescents 12-15 years old.
COVID-19 Updates
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
transplantation or
have an equivalent level of immune compromise.1,2
2. Booster doses of the vaccine are now ...
On January 3, the FDA amended its Emergency
Use Authorization (EUA) for the Pfizer-BioNTech
COVID-19 vaccine (Comirnaty) to incorporate the
following changes. The anti-SARS-CoV-2 antibody combinations
casirivimab plus imdevimab (REGEN-COV) and
bamlanivimab plus etesevimab are not active
against the Omicron variant of SARS-CoV-2.
COVID-19 Update: Booster Dose of the Pfizer Vaccine for Children 5-11 Years Old
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
COVID-19 Update: Booster Dose of the Pfizer Vaccine for Children 5-11 Years Old ...
The FDA has expanded its Emergency Use Authorization for the mRNA COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) to include administration of a booster dose in children 5-11 years old who completed a primary series of the Pfizer vaccine ≥5 months previously.
Prevention and Treatment of Monkeypox
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
vaccination)
No Yes (at the vaccination site; can take ≥6 weeks to
heal)
Immune response 2 weeks after 2nd ...
An outbreak of monkeypox has recently spread around
the globe and across the US. Updated information
about the current outbreak is available from the CDC.
In Brief: Two Doses of Jynneos for Mpox (online only)
The Medical Letter on Drugs and Therapeutics • Jun 02, 2023 (Issue 5065)
Table 1) receive two doses of
the Jynneos vaccine. The recommendation follows
reports of a recent ...
The CDC is recommending that persons at high
risk of mpox (see Table 1) receive two doses of
the Jynneos vaccine. The recommendation follows
reports of a recent cluster of mpox cases in the US
and warnings about the risk of a renewed outbreak
during the spring and summer as people gather
for festivals and other events. The CDC does not
recommend routine immunization against mpox for
the general population.
Med Lett Drugs Ther. 2023 Jun 2;65(5065):1-2 doi:10.58347/tml.2023.5065a | Show Introduction Hide Introduction
COVID-19 Updates
The Medical Letter on Drugs and Therapeutics • Apr 18, 2022 (Issue 1648)
COVID-19 UPDATES
Second Booster Vaccine Dose for Older and Immunocompromised Persons
The FDA ...
The FDA has expanded the Emergency Use Authorizations
(EUAs) for the mRNA COVID-19 vaccines
manufactured by Pfizer-BioNTech (Comirnaty) and
Moderna (Spikevax) to allow for their use as a second
booster dose ≥4 months after a first booster dose in
adults ≥50 years old and in persons aged ≥12 years
(Pfizer) or ≥18 years (Moderna) who have undergone
solid organ transplantation or have a condition that
compromises the immune system to a similar extent.
In Brief: Shingrix for Immunocompromised Adults
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
recommendations from the
Advisory Committee on Immunization Practices
(ACIP) on use of the vaccine ...
The FDA has licensed the adjuvanted, recombinant
varicella zoster virus (VZV) vaccine Shingrix (GSK) for
prevention of herpes zoster (shingles) in adults of any
age who are or will be at elevated risk because of disease-
or therapy-induced immunodeficiency or immunosuppression.
Shingrix has been licensed for herpes
zoster prevention in adults ≥50 years old since 2017.1
It is the only VZV vaccine currently available in the US;
Zostavax, a live-attenuated VZV vaccine, was withdrawn
from the market in 2020.
Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 10, 2022 (Issue 1641)
allergy that prevents their
vaccination against COVID-19 or moderate or severe
immune compromise (see ...
The FDA has issued an Emergency Use Authorization
(EUA) for the investigational long-acting monoclonal
antibodies tixagevimab and cilgavimab (Evusheld –
AstraZeneca) to be administered concomitantly by IM
injection for pre-exposure prophylaxis of COVID-19 in
persons ≥12 years old who weigh ≥40 kg and have
either a history of severe allergy that prevents their
vaccination against COVID-19 or moderate or severe
immune compromise (see Table 1). They are the first
drugs to be authorized by the FDA for this indication.
Two other pairs of antibodies, bamlanivimab plus
etesevimab...
Figure 2: Pneumococcal Vaccine Recommendations for Adults ≥65 Years Old (online only)
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024 (Issue 1713)
Figure 2: Pneumococcal Vaccine Recommendations for Adults ≥65 Years Old (online only) ...
View Figure 2: Pneumococcal Vaccine Recommendations for Adults ≥65 Years Old
Med Lett Drugs Ther. 2024 Oct 14;66(1713):e164 doi:10.58347/tml.2024.1713g | Show Introduction Hide Introduction